Clinical Policy: Diazoxide Choline (Vykat XR)
Customize your policy alerts
Sign up for Ambetter Nevada Policy CP.PHAR.701 alerts
Get alerted when Policy CP.PHAR.701 changes without checking for updates manually.
Monitor payer policy activity
This policy governs prior authorization and medical-necessity coverage of Vykat XR for hyperphagia in adults and pediatric members age 4 years and older with Prader-Willi syndrome. It applies to Ambetter Nevada commercial, HIM/ICHRA, and Medicaid lines of business, subject to applicable benefit documents and state Medicaid requirements.
The 2026 annual revision added the health insurance marketplace/ICHRA line of business.
The PWS diagnosis criterion was revised to require genetic testing indicating a mutation on chromosome 15.
The policy previously removed the upper weight limit of 135 kg and several continued-therapy response parameters, including CGI-I, GI-C, body-composition components, and behavioral improvements.
The continued-therapy approval duration was revised from 6 months to 12 months.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.